Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06869577
Starting soon Not applicable

A Supportive Group Intervention for Caregivers to Patients Diagnosed With a Glioblastoma

NCT06869577 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital, Rigshospitalet
Phase
Not applicable
Started
2025-05-01
Last updated
2025-04-29

Condition(s) studied

CaregiverGlioblastoma Multiform (Grade IV Astrocytoma)

Investigational drug(s) / intervention(s)

Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma

Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma: A 12-week supportive group intervention targeted caregivers to patients with glioblastoma.

Study summary

Feasibility test and evaluation of a group intervention for caregivers to patients diagnosed with a glioblastoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Family caregivers (≥18 years) to patients (≥18 years) diagnosed with a GBM grade IV or diffuse astrocytoma grade IV offered Stupps treatment regime. Exclusion Criteria: * Participants who do not understand, read, and speak Danish.

Primary outcome measure(s)

  • Feasibility parametres — The final evaluation of the feasibility of the intervention will be conducted after the completion of the intervention, which is scheduled to last 12 weeks.
    The primary outcome is the feasibility of the intervention. Accurate feasibility parameters will be outlined when the intervention is fully designed. However, we will most likely access recruitment rate, adherence to the overall intervention, acceptability, and safety. We will establish the final percentages for feasibility within each parameter prior test of the intervention and use these to report the overall feasibility of the intervention. Final percentages will be guided by other feasibility studies within the neuro-oncology field.
  • Feasibility parametres — The final evaluation of the feasibility of the intervention will be conducted after the completion of the intervention, which is scheduled to last 12 weeks.
    Feasibility of the intervention will also be accessed by a survey. We will develop a study specific questionnaire to evaluate the content and overall intervention. The questionnaire will apply a 5-point Likert scale to evaluate the intervention. The questionnaire will be developed when the final intervention is designed.

Trial sites (1)

FacilityCityRegionStatus
Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark

More Copenhagen University Hospital, Rigshospitalet trials in Denmark

Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria Recruiting
Immediate Versus Postponed Single Blastocyst Transfer in mNC-FET Active, not recruiting
The Copenhagen Gender Identity Cohort Recruiting
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection Recruiting
Precision Medicine in the Depression Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06869577 on ClinicalTrials.gov ↗ ← All trials in Denmark